LLY · 8-K · 20260805PR000077
Headcount / Restructuring
ELI LILLY & Co · 2026-08-05 · Importance 71 · Surprise 82 · In source text
Lilly recorded $703 million of asset impairment, restructuring, and other special charges in Q2 2026, compared with no such charges in Q2 2025. The charges primarily reflected accelerated vesting of employee equity awards and acquisition and integration costs related to Kelonia Therapeutics and Centessa Pharmaceuticals. The company did not disclose a specific headcount reduction or facility-exit program in the release.
Key facts
- Asset impairment, restructuring and other special charges of $703 million in Q2 2026 were primarily related to accelerated vesting of employee equity awards and acquisition and integration costs associated with Kelonia and Centessa acquisitions. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | realized | -3.1% | Asset impairment, restructuring and other special charges of $703 million in Q2 2026 were primarily related to accelerated vesting of… |
| net_income | negative | realized | — | Asset impairment, restructuring and other special charges of $703 million in Q2 2026 were primarily related to accelerated vesting of… |